Trial · NCT01531959

Midodrine for the Treatment of Refractory Hypotension

NCT01531959, Phase 3, Completed, Massachusetts General Hospital; results first posted 2019-09-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Midodrine for the Treatment of Refractory Hypotension. Trials, record NCT01531959. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01531959

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Midodrine for the Treatment of Refractory Hypotension
NCT number: NCT01531959
Status: Completed
Phases: Phase 3
Enrollment: 139 participants, actual
Lead sponsor: Massachusetts General Hospital
Conditions: Hypotension, Critical Illness
Interventions: Midodrine, Placebo
First posted: 2012-02-13
Last updated: 2020-10-28
Results first posted: 2019-09-06

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Time Until Discontinuation of IV Vasopressors	From initiation of the study drug until discontinuation of IV vasopressors, assessed up to 400 hours	Measured hours from initiation of midodrine until discontinuation of IV vasopressors
Secondary	ICU Length of Stay	From initiation of midodrine until ICU discharge, assessed up to 45 days	Measured number of days from initiation of midodrine until discharge ready from the ICU
Secondary	Hospital Length of Stay	From initiation of midodrine until hospital discharge, assessed up to 90 days	Measured number of days from initiation of midodrine until discharged from hospital
Secondary	Rates of ICU Readmission	Up to 2 months after ICU discharge	Number of patients initiated on midodrine that are readmitted back to ICU after being discharged to floor
Secondary	Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias	From initiation of the study drug until discontinuation of the study drug, an average of 59 hours.	Measured rates of hypertension (increase in systolic blood pressure to values higher than those set by the primary team or greater than 160 mmg), bradycardia (decrease in heart rate to values lower than those set by the primary team or less than 40 BPM), hemodynamically significant tachyarrythmias (greater than 20 mmhg decrease in systolic blood pressure).

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Time Until Discontinuation of IV Vasopressors	From initiation of the study drug until discontinuation of IV vasopressors, assessed up to 400 hours	hours	MEDIAN
SECONDARY	ICU Length of Stay	From initiation of midodrine until ICU discharge, assessed up to 45 days	days	MEDIAN
SECONDARY	Hospital Length of Stay	From initiation of midodrine until hospital discharge, assessed up to 90 days	days	MEDIAN
SECONDARY	Rates of ICU Readmission	Up to 2 months after ICU discharge	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias	From initiation of the study drug until discontinuation of the study drug, an average of 59 hours.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Time Until Discontinuation of IV Vasopressors	Midodrine	23.5	Inter-Quartile Range 10.0 to 54.0	hours
Time Until Discontinuation of IV Vasopressors	Placebo	22.5	Inter-Quartile Range 10.4 to 40.0	hours
ICU Length of Stay	Midodrine	6.0	Inter-Quartile Range 5.0 to 8.0	days
ICU Length of Stay	Placebo	6.0	Inter-Quartile Range 4.0 to 8.0	days
Hospital Length of Stay	Midodrine	11.0	Inter-Quartile Range 9.0 to 21.0	days
Hospital Length of Stay	Placebo	14.0	Inter-Quartile Range 9.0 to 22.0	days
Rates of ICU Readmission	Midodrine	1		Participants
Rates of ICU Readmission	Placebo	3		Participants
Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias	Midodrine	12		Participants
Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias	Placebo	3		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Midodrine	68
Overall Study	STARTED	Placebo	68
Overall Study	COMPLETED	Midodrine	66
Overall Study	COMPLETED	Placebo	66
Overall Study	NOT COMPLETED	Midodrine	2
Overall Study	NOT COMPLETED	Placebo	2

Source ClinicalTrials.gov

Adverse events44

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hypertension	Cardiac disorders	Midodrine	7	66	7
other	Hypertension	Cardiac disorders	Placebo	3	66	3
other	Bradycardia	Cardiac disorders	Midodrine	5	66	5
other	Bradycardia	Cardiac disorders	Placebo	0	66	0
other	Atrial fibrillation	Cardiac disorders	Midodrine	3	66	3
other	Atrial fibrillation	Cardiac disorders	Placebo	1	66	1
other	Nausea	Gastrointestinal disorders	Midodrine	2	66	2
other	Nausea	Gastrointestinal disorders	Placebo	1	66	1
other	Lab parameter change	Investigations	Midodrine	2	66	2
other	Lab parameter change	Investigations	Placebo	1	66	1

1 to 10 of 44Source ClinicalTrials.gov

See all 44 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Midodrine	0	66
Total, all-cause mortality	Placebo	1	66
Total, other adverse events	Midodrine	20	66
Total, other adverse events	Placebo	17	66
Total, serious adverse events	Midodrine	0	66
Total, serious adverse events	Placebo	1	66

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
28327122	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Midodrine vs Placebo: Rates of ICU Readmission	Trial comparisons
Midodrine vs Placebo: deaths from any cause	Trial comparisons
Midodrine vs Placebo: Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias	Trial comparisons
Midodrine vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01531959

GET https://conductscience.org/api/trials/v1/NCT01531959/events?page=2

API reference For AI assistants